We hypothesize that the immune system of ACPA-positive individuals at risk of developing RA strives to reduce inflammation by upregulating miR-451, which subsequently downregulates CXCL16 expression in monocytes and thereby delays the shift from the preclinical phase to the clinical manifestation of arthritis. The gene discussed is PRTN3; the disease is rheumatoid arthritis.